Practical Approaches to the Use of Lenalidomide in Multiple Myeloma: A Canadian Consensus

Table 1

Dose adjustments at the start of therapy according to renal function [14].

Renal function	Dose*
Mild renal impairment ( 60 ≤ CrCl < 90 mL/min)	25 mg (normal dose) every 24 hours
Moderate renal impairment (30 ≤ CrCl < 60 mL/min)	10 mg^† every 24 hours
Severe renal impairment (CrCl < 30 mL/min, not requiring dialysis)	15 mg every 48 hours
End-stage renal disease (CrCl < 30 mL/min, requiring dialysis)	5 mg once daily. On dialysis days, the dose should be administered following dialysis

*While maintaining a treatment cycle of 21 out of 28 days.
^†Dose may be escalated to 15 mg once daily after two cycles if patient does not respond to and is tolerating treatment.
CrCl: creatinine clearance.